Clinical Experience of Patients Referred to a Multidisciplinary Cardiac Oncology Clinic: An Observational Study

Table 2

Cancer therapy ().

	(%)
Cancer therapy	= 405
(i) First-line chemotherapy alone	169 (41.7%)
(ii) First-line targeted therapy alone^*	24 (5.9%)
(iii) First-line combined therapy (chemotherapy and targeted therapy)	163 (40.2%)
(iv) Second-line therapy (chemotherapy and/or targeted therapy)	128 (31.6%)
First-line chemotherapy alone	= 169
(i) Anthracycline-based	84 (49.7%)
(ii) Non-anthracycline-based	85 (50.3%)
(iii) Median anthracycline dose	277 mg/m^2 (r: 46–4803)
Number of chemotherapy cycles (median)
(i) First-line chemotherapy	6 (r: 0–59 cycles)
(ii) Second-line chemotherapy	5.5 (r: 0–33 cycles)

Targeted therapy examples: trastuzumab, sunitinib, bevacizumab, sorafenib, and imatinib.